SCHEMBL9105855

SCHEMBL9105855

CC(=O)Nc1cc(-c2nc(-c3cc(CN4CCCC4)ccc3Cl)c(C(=O)O)o2)c(C)cn1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 1/20 0.39
F10 P00742 2/20 0.38
HRH3 Q9Y5N1 1/20 0.38
GAA P10253 2/20 0.38
USP2 O75604 1/20 0.38
WDR5 P61964 1/20 0.37
PIK3C3 Q8NEB9 1/20 0.37
SSTR5 P35346 1/20 0.36
ABL1 P00519 2/20 0.35
PDK1 Q15118 1/20 0.35
MAPK1 P28482 1/20 0.35
CCR3 P51677 2/20 0.35
CNR2 P34972 2/20 0.35
CNR1 P21554 1/20 0.35
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9888724 0.93 KDM4E (0.38) KDM4EALDH1A1F10HRH3GAA
SCHEMBL9888752 0.85 USP2 (0.36) KDM4EALDH1A1F10HRH3GAA
SCHEMBL626945 0.81 PIK3C3 (0.45) KDM4EALDH1A1PIK3C3ABL1CNR2
SCHEMBL10182421 0.77 CDK9 (0.32) PIK3C3
SCHEMBL9890040 0.76 WDR5 (0.36) KDM4EALDH1A1F10WDR5CNR2
SCHEMBL9108830 0.76 KDM4E (0.36) KDM4EALDH1A1F10HRH3GAA
SCHEMBL626067 0.73 PIK3C3 (0.42) KDM4EALDH1A1PIK3C3ABL1CNR2
SCHEMBL15051430 0.71 KDM4E (0.39) KDM4EALDH1A1F10HRH3GAA
SCHEMBL626417 0.70 PIK3C3 (0.39) KDM4EPIK3C3ABL1HSP90AA1HSP90AB1
SCHEMBL9106023 0.70 S1PR4 (0.35) ALDH1A1F10PIK3C3ABL1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859768-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-10-14 US disclosed
US-8859768-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-10-14 US disclosed
US-8859768-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-10-14 US disclosed
US-20120142732-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
US-20120142732-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
US-20120142732-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142732-A1 HETEROARYLS AND USES THEREOF PIK3R4, PIK3C2B, PIK3R1 KDM4E 2506/4885ALDH1A1 1905/4885F10 4242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.